We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


The Story of Developing Campath for the Treatment of Multiple Sclerosis


The Story of Developing Campath for the Treatment of Multiple Sclerosis

Who's speaking at this Webinar?

Alasdair Coles
Professor Neuroimmunology University of Cambridge

The autoimmune disease multiple sclerosis (MS) targets the protective myelin sheath that coats axons in the central nervous system. MS can cause lifelong disability, and strike early in life, meaning developing effective therapies has been a primary aim of research.

Professor Alasdair Coles has been involved in the development of drugs to treat MS for over twenty years. His work with Alastair Compston was instrumental in the identification of Campath (Alemtuzumab), a humanized monoclonal antibody, as an effective treatment for MS.

In this webinar, Professor Coles will outline the history of Campath’s development, exploring how drug companies, scientists and patients all play a role in the success of pharmacological treatment.

Attend this webinar to hear:

How antibody-based compounds have revolutionized treatment of MS
The latest exciting developments in MS therapeutics
The inside story of how antibodies are developed into effective therapies for brain diseases 


To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free